Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TYRA 
Tyra Biosciences Inc (TYRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TYRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32
1 Year Target Price $32
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.93% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 790.93M USD | Price to earnings Ratio - | 1Y Target Price 32 |
Price to earnings Ratio - | 1Y Target Price 32 | ||
Volume (30-day avg) 8 | Beta 1.11 | 52 Weeks Range 6.42 - 29.60 | Updated Date 10/17/2025 |
52 Weeks Range 6.42 - 29.60 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.79 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.29% | Return on Equity (TTM) -31.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 423400704 | Price to Sales(TTM) - |
Enterprise Value 423400704 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.95 | Shares Outstanding 53297140 | Shares Floating 17218174 |
Shares Outstanding 53297140 | Shares Floating 17218174 | ||
Percent Insiders 3.68 | Percent Institutions 106.6 |
Upturn AI SWOT
Tyra Biosciences Inc
Company Overview
History and Background
Tyra Biosciences Inc. was founded in 2018 and focuses on developing precision medicines to overcome acquired resistance in cancer. The company went public in 2021.
Core Business Areas
- Precision Oncology: Tyra is focused on designing and developing drugs that target specific genetic mutations in cancer cells, particularly those related to acquired resistance. Their leading drug candidate is TYRA-300.
Leadership and Structure
The leadership team includes executives with experience in drug development and oncology. The company has a board of directors that provides oversight and guidance.
Top Products and Market Share
Key Offerings
- TYRA-300: TYRA-300 is Tyra's leading drug candidate, a small molecule inhibitor targeting FGFR3 mutations. This is in clinical trials and there is no market share or revenue yet. Competitors include Blueprint Medicines (BPMC) and QED Therapeutics. Total Users and Revenue are unavailable as it is still in development.
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market, driven by advancements in personalized medicine and targeted therapies. There is a high unmet need for therapies that overcome acquired resistance.
Positioning
Tyra is positioned as a precision oncology company focused on developing innovative therapies for patients with resistant cancers. Their competitive advantage lies in their proprietary SNAP platform which speeds drug discovery and reduces off target binding.
Total Addressable Market (TAM)
The global oncology market is projected to reach trillions of dollars, making the TAM significant. Tyra is specifically targeting niche markets within oncology (FGFR3) to obtain a substantial market share.
Upturn SWOT Analysis
Strengths
- Proprietary SNAP platform
- Experienced leadership team
- Focus on overcoming acquired resistance
- Strong intellectual property position
Weaknesses
- Limited number of products in development
- High reliance on clinical trial success
- Significant cash burn
Opportunities
- Expansion of pipeline through SNAP platform
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results for TYRA-300
- Regulatory approval for TYRA-300
Threats
- Clinical trial failures
- Competition from other oncology drug developers
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BPMC
- EQRX
- BLU
Competitive Landscape
Tyra operates in a competitive landscape with both established pharmaceutical companies and emerging biotech firms. Their competitive advantage lies in their innovative SNAP platform and focus on overcoming acquired resistance.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by pipeline development and clinical trial progress.
Future Projections: Future growth is dependent on the success of TYRA-300 and other pipeline candidates. Analyst estimates vary widely depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing TYRA-300 through clinical trials and expanding the pipeline with new drug candidates from the SNAP platform.
Summary
Tyra Biosciences is a clinical-stage biopharmaceutical company focused on precision oncology. Its strength lies in its SNAP platform, but it faces risks associated with clinical trial success and competition. Future success relies on advancing its pipeline and securing regulatory approvals. Tyra is a high-risk, high-reward investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company press releases
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on available information and may not be completely accurate or up-to-date. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tyra Biosciences Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2021-09-15 | Co-Founder, President, CEO, Secretary, Treasurer & Director Dr. Todd Harris Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://tyra.bio |
Full time employees 60 | Website https://tyra.bio | ||
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.